Company No: 08423097 (England and Wales)

Contents

• Company Information
• Balance Sheet
• Notes to the Financial Statements

DIRECTORS	Xander James Corrie (Appointed 26 February 2026)
	Ian Robert Swift (Resigned 26 February 2026)

SECRETARY

Xander James Corrie

REGISTERED OFFICE	Biocentre York Science Park
	Heslington
	York
	YO10 5DG
	United Kingdom

COMPANY NUMBER

08423097 (England and Wales)

ACCOUNTANT	Inglis
	Wellington House
	Aviator Court
	Clifton Moor
	York
	YO30 4UZ
	United Kingdom

	Note	2026		2025
		£		£
Fixed assets
Tangible assets	3	496		662
		496		662
Current assets
Debtors	4	35,389		35,122
Cash at bank and in hand	5	21,172		8,759
		56,561		43,881
Creditors: amounts falling due within one year	6	( 5,365)		( 1,202)
Net current assets		51,196		42,679
Total assets less current liabilities		51,692		43,341
Net assets		51,692		43,341
Capital and reserves
Called-up share capital	7	100		100
Profit and loss account		51,592		43,241
Total shareholders' funds		51,692		43,341

For the financial year ending 31 January 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
• These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Clinical And Evidential Storage Ltd. (registered number: 08423097) were approved and authorised for issue by the Director on 14 May 2026. They were signed on its behalf by:

Xander James Corrie Director

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Clinical And Evidential Storage Ltd. (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Biocentre York Science Park, Heslington, York, YO10 5DG, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Fixtures and fittings

25 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

2. Employees

	2026		2025
	Number		Number
Monthly average number of persons employed by the Company during the year, including the director	1		1

3. Tangible assets

	Fixtures and fittings		Total
	£		£
Cost
At 01 February 2025	4,070		4,070
At 31 January 2026	4,070		4,070
Accumulated depreciation
At 01 February 2025	3,408		3,408
Charge for the financial year	166		166
At 31 January 2026	3,574		3,574
Net book value
At 31 January 2026	496		496
At 31 January 2025	662		662

4. Debtors

	2026		2025
	£		£
Trade debtors	34,496		34,729
Other debtors	893		393
	35,389		35,122

5. Cash and cash equivalents

	2026		2025
	£		£
Cash at bank and in hand	21,172		8,759

6. Creditors: amounts falling due within one year

	2026		2025
	£		£
Trade creditors	286		492
Other taxation and social security	0		10
Other creditors	5,079		700
	5,365		1,202

7. Called-up share capital

	2026		2025
	£		£
Allotted, called-up and fully-paid
100 Ordinary shares of £ 1.00 each	100		100